Published in Medical Letter on the CDC and FDA, April 10th, 2005
"The American Academy of Dermatology is disappointed that the FDA has taken this action, despite the fact that there is no data that proves proper topical use of pimecrolimus and tacrolimus is dangerous in people," said dermatologist Clay J. Cockerell, MD, president of the American Academy of Dermatology.
"Because these medications are applied to the skin,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA